赛妥珠单抗聚乙二醇在非放射性轴性脊柱关节炎中的快速疗效。

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis.

作者信息

Spadaro A, Scarno A, Carboni A, Perrotta F M, Catalano C, Lubrano E, Valesini G

机构信息

Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università La Sapienza, Roma, Italy.

出版信息

Reumatismo. 2013 Jul 24;65(3):134-7. doi: 10.4081/reumatismo.2013.134.

DOI:10.4081/reumatismo.2013.134

PMID:23884030

Abstract

In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.

摘要

在轴向型脊柱关节炎（SpA）中，新型聚乙二醇化抗肿瘤坏死因子α药物赛妥珠单抗（CZP）的疗效尚未得到研究。我们报告，根据国际脊柱关节炎评估协会（ASAS）标准分类，一名非放射学轴向型SpA患者经临床和磁共振成像评估显示，CZP具有快速疗效。该病例表明，CZP可被视为非放射学轴向型SpA的一种有效治疗方法，支持早期治疗方法在该疾病管理中可能发挥重要作用。